Nplate Related Published Studies
Well-designed clinical trials related to Nplate (Romiplostim Subcutaneous)
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. [2011.07.07]
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. [2011.07]
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. [2011.03.01]
Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the
treatment of immune thrombocytopenia (ITP). [2011]
Romiplostim or standard of care in patients with immune thrombocytopenia. [2010.11.11]
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. [2010.10.28]
Evaluation of bleeding and thrombotic events during long-term use of romiplostim
in patients with chronic immune thrombocytopenia (ITP). [2010]
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. [2009.10.29]
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. [2009.07]
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. [2009.02]
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. [2008.02.02]
Well-designed clinical trials possibly related to Nplate (Romiplostim Subcutaneous)
Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. [2009.02]
Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. [2008]
Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. [2007.12]
Other research related to Nplate (Romiplostim Subcutaneous)
Health-related quality of life in nonsplenectomized immune thrombocytopenia
patients receiving romiplostim or medical standard of care. [2012]
Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue. [2011.12.02]
Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. [2011.11]
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. [2011.10.20]
Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). [2011.09.09]
Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. [2011.07]
The development of romiplostim for patients with immune thrombocytopenia. [2011.03]
Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. [2011.03]
Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). [2011.01]
Romiplostim. [2011]
[Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura]. [2010.12]
Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim. [2010.08]
Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. [2010.07.14]
Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. [2010.07]
Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. [2010.07]
Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). [2010.06]
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. [2010.01.20]
Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. [2009.09]
Romiplostim in chronic immune thrombocytopenic purpura. [2009.09]
A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. [2009.09]
Romiplostim: a novel thrombopoiesis-stimulating agent. [2009.05.01]
Romiplostim management of immune thrombocytopenic purpura. [2009.05]
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. [2009.03.05]
Romiplostim: a second-generation thrombopoietin agonist. [2009.03]
Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. [2009.03]
Degarelix. [2009]
Romiplostim. [2008.11]
Other possibly related research studies
Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. [2009]
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. [2009.06]
Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia. [2009.02]
Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. [2009.01]
New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. [2009.05.02]
Chronic immune thrombocytopenic purpura. New agents. [2009.01]
New options after first-line therapy for chronic immune thrombocytopenic purpura. [2009.01.15]
The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. [2008.11]
[Novel medical treatment modalities in hematology] [2008.06.09]
The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. [2008.07]
Overview of thrombopoietic agents in the treatment of thrombocytopenia. [2008.02]
New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. [2008.02]
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. [2008.01]
[New treatment methods for autoimmune thrombocytopenia] [2007.11.24]
New insights and therapeutics for immune-mediated thrombocytopenia. [2008.01]
New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review. [2008.01]
A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. [2007.05]
Toxicities of the thrombopoietic growth factors. [2010.07]
Thrombopoietic agents in immune thrombocytopenia. [2010.07]
Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. [2010.08]
Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. [2010.01]
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? [2009]
Treatment of MDS: something old, something new, something borrowed... [2009]
New thrombopoietic growth factors. [2009]
Development of thrombopoietin receptor agonists for clinical use. [2009.07]
Thrombopoietin receptor agonists in the treatment of thrombocytopenia. [2009.09]
Review Article: Second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. [2010.06]
Gateways to clinical trials. [2007.11]
Hematopoietic growth factors in myelodysplastic syndromes. [2011.10]
TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. [2011.07.06]
Romiplostin may revert the thrombocytopenia in graft-versus-host disease. [2011.03]
Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics. [2011]
Current treatment options for primary immune thrombocytopenia. [2011.02]
[New treatment options for primary immune thrombocytopenia]. [2011.01.24]
Current status of thrombopoietic agents. [2010.04]
Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. [2010.12]
The management of peripheral blood cytopenias in systemic lupus erythematosus. [2010.12]
Thrombocytopenia in patients with myelodysplastic syndromes. [2010.07]
Biology and chemistry of thrombopoietic agents. [2010.07]
Current and future management options for myelodysplastic syndromes. [2010.07.30]
Thrombopoietic agents. [2010.07]
Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care? [2010.12]
Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura. [2011.03]
Bleeding and mortality outcomes in ITP clinical trials: a review of
thrombopoietin mimetics data. [2012]
TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. [2011]
Thrombopoietin receptor agonists in primary immune thrombocytopenia. [2013]
Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic
syndromes: a systematic review and meta-analysis of randomized controlled trials. [2014]
|